Bradley Watts, DO
Family Medicine · Salt Lake City, UTNPI 1043741929
Payments from drug & device makers
Across 162 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$735
- Lilly USA, LLC$441
- Novo Nordisk$363
- Merck$120
- Dynavax Technologies Corporation$103
- Bayer$100
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,895100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $735 |
| Lilly USA, LLC | 29 | $441 |
| Novo Nordisk | 18 | $363 |
| Merck | 7 | $120 |
| Dynavax Technologies Corporation | 5 | $103 |
| Bayer | 6 | $100 |
| AstraZeneca | 6 | $92 |
| Ultragenyx Pharmaceutical Inc. | 3 | $59 |
| Lucid Diagnostics Inc. | 4 | $56 |
| Edwards Lifesciences | 2 | $56 |
| Organon | 4 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Viiv Healthcare Company | 2 | $45 |
| Johnson & Johnson | 2 | $45 |
| Exact Sciences | 3 | $45 |
| Boehringer Ingelheim | 2 | $42 |
| Medtronic | 3 | $39 |
| Gilead | 2 | $36 |
| Inspire Medical Systems, Inc. | 2 | $33 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Pfizer | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| GSK | 2 | $30 |
| Mayne Pharma Commercial LLC | 1 | $26 |
| Corcept Therapeutics | 1 | $24 |
| Shield Therapeutics Inc | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Qorumpartners | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
| Abbott | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$122
How this compares
$2,907 in reported general payments places this provider in the 75th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 171 | $157,069 |
| RybelsusSemaglutide | 58 | $76,183 |
| OzempicSemaglutide | 60 | $61,702 |
| VraylarCariprazine Hcl | 27 | $39,620 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $32,482 |
| EliquisApixaban | 32 | $26,616 |
| TrulicityDulaglutide | 15 | $25,054 |
| FarxigaDapagliflozin Propanediol | 15 | $20,469 |
| MounjaroTirzepatide | 14 | $17,195 |
| SynjardyEmpagliflozin/Metformin Hcl | 15 | $15,756 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $12,643 |
| JanuviaSitagliptin Phosphate | 15 | $8,750 |
| Spiriva HandihalerTiotropium Bromide | 11 | $6,379 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,542 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Combivent Respimat | $42 | $178,366197 claims |
| Novo NordiskRybelsus, Ozempic | $363 | $137,884118 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $441 | $42,24929 claims |
| AbbVieVraylar | $735 | $39,62027 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $30 | $37,26753 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $92 | $33,11233 claims |
| PfizerEliquis | $31 | $26,61632 claims |
| MerckJanuvia | $120 | $8,75015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 928 family medicine providers in Utah.
Other family medicine in Salt Lake City
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Sarang YoonSalt Lake City$9.4M
- Stephen ColemanSalt Lake City$2M
- Albert JarviSalt Lake City$1.6M
- Derek MuseSalt Lake City$1.3M
- David LarsenSalt Lake City$1.2M
- Mara RabinSalt Lake City$1.1M
- John WitbeckSalt Lake City$235K
- Mark JohnsonSalt Lake City$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.